{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:22:31Z","timestamp":1792790551361,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s40618-020-01226-4","type":"journal-article","created":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T13:03:22Z","timestamp":1585746202000},"page":"1473-1483","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study"],"prefix":"10.1007","volume":"43","author":[{"given":"X.","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5515-730X","authenticated-orcid":false,"given":"Xiahong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,1]]},"reference":[{"key":"1226_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11523-017-0549-7","volume":"13","author":"JM Clarke","year":"2018","unstructured":"Clarke JM, George DJ, Lisi S, Salama AKS (2018) Immune checkpoint blockade: the new frontier in Cancer treatment. Target Oncol 13:1\u201320. https:\/\/doi.org\/10.1007\/s11523-017-0549-7","journal-title":"Target Oncol"},{"key":"1226_CR2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s11523-016-0471-4","volume":"12","author":"J Martin-Liberal","year":"2017","unstructured":"Martin-Liberal J, Hierro C, Ochoa de Olza M, Rodon J (2017) Immuno-oncology: the third paradigm in early drug development. Target Oncol 12:125\u2013138. https:\/\/doi.org\/10.1007\/s11523-016-0471-4","journal-title":"Target Oncol"},{"key":"1226_CR3","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s40618-018-0984-z","volume":"42","author":"RM Ruggeri","year":"2019","unstructured":"Ruggeri RM, Campenn\u00ec A, Giuffrida G, Trimboli P, Giovanella L, Trimarchi F, Cannav\u00f2 S (2019) Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know). J Endocrinol Invest 42:745\u2013756. https:\/\/doi.org\/10.1007\/s40618-018-0984-z","journal-title":"J Endocrinol Invest"},{"key":"1226_CR4","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36:1714\u20131768. https:\/\/doi.org\/10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"key":"1226_CR5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nrendo.2016.205","volume":"13","author":"DJ Byun","year":"2017","unstructured":"Byun DJ, Wolchok JD, Rosenberg LM, Girotra M (2017) Cancer immunotherapy: immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol 13:195\u2013207. https:\/\/doi.org\/10.1038\/nrendo.2016.205","journal-title":"Nat Rev Endocrinol"},{"key":"1226_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/EJE-19-0535","volume":"182","author":"X Bai","year":"2020","unstructured":"Bai X, Chen X, Wu X, Huang Y, Zhuang Y, Lin X (2020) Immune checkpoint inhibitor-associated thyroid dysfunction: a disproportionality analysis using the WHO Adverse Drug Reaction Database, VigiBase. Eur J Endocrinol 182:1\u20139. https:\/\/doi.org\/10.1530\/EJE-19-0535","journal-title":"Eur J Endocrinol"},{"key":"1226_CR7","doi-asserted-by":"publisher","first-page":"R107","DOI":"10.1530\/EJE-19-0169","volume":"181","author":"F Albarel","year":"2019","unstructured":"Albarel F, Castinetti F, Brue T (2019) MANAGEMENT OF ENDOCRINE DISEASE: Immune check point inhibitors-induced hypophysitis. Eur J Endocrinol 181:R107\u2013R118. https:\/\/doi.org\/10.1530\/EJE-19-0169","journal-title":"Eur J Endocrinol"},{"key":"1226_CR8","doi-asserted-by":"publisher","first-page":"k793","DOI":"10.1136\/bmj.k793","volume":"360","author":"S Baxi","year":"2018","unstructured":"Baxi S, Yang A, Gennarelli RL, Khan N, Wang Z, Boyce L, Korenstein D (2018) Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ 360:k793. https:\/\/doi.org\/10.1136\/bmj.k793","journal-title":"BMJ"},{"key":"1226_CR9","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s40261-018-0735-0","volume":"39","author":"HH Ji","year":"2019","unstructured":"Ji HH, Tang XW, Dong Z, Song L, Jia YT (2019) Adverse event profiles of anti-CTLA-4 and anti-PD-1 monoclonal antibodies alone or in combination: analysis of spontaneous reports submitted to FAERS. Clin Drug Investig 39:319\u2013330. https:\/\/doi.org\/10.1007\/s40261-018-0735-0","journal-title":"Clin Drug Investig"},{"key":"1226_CR10","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s40425-019-0754-2","volume":"7","author":"Y Zhai","year":"2019","unstructured":"Zhai Y, Ye X, Hu F, Xu J, Guo X, Zhuang Y, He J (2019) Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system. J Immunother Cancer 7:286. https:\/\/doi.org\/10.1186\/s40425-019-0754-2","journal-title":"J Immunother Cancer"},{"key":"1226_CR11","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s11523-019-00632-w","volume":"14","author":"E Raschi","year":"2019","unstructured":"Raschi E, Mazzarella A, Antonazzo IC, Bendinelli N, Forcesi E, Tuccori M, Moretti U, Poluzzi E, De Ponti F (2019) Toxicities with immune checkpoint inhibitors: emerging priorities from disproportionality analysis of the FDA adverse event reporting system. Target Oncol 14:205\u2013221. https:\/\/doi.org\/10.1007\/s11523-019-00632-w","journal-title":"Target Oncol"},{"key":"1226_CR12","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1177\/009286150804200501","volume":"42","author":"M Lindquist","year":"2008","unstructured":"Lindquist M (2008) VigiBase, the WHO global ICSR database system: basic facts. Drug Inf J 42:409\u2013419. https:\/\/doi.org\/10.1177\/009286150804200501","journal-title":"Drug Inf J"},{"key":"1226_CR13","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, De Freitas RM (1998) A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 54:315\u2013321. https:\/\/doi.org\/10.1007\/s002280050466","journal-title":"Eur J Clin Pharmacol"},{"key":"1226_CR14","unstructured":"Uppsala Monitoring Centre (UMC). Analytical methods developed by the UMC Research team are integrated in VigiLyze. https:\/\/www.who-umc.org\/vigibase\/vigilyze\/analytics-in-vigilyze. Accessed 30 Jul 2019"},{"key":"1226_CR15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0962280211403604","volume":"22","author":"GN Nor\u00e9n","year":"2013","unstructured":"Nor\u00e9n GN, Hopstadius J, Bate A (2013) Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res 22:57\u201369. https:\/\/doi.org\/10.1177\/0962280211403604","journal-title":"Stat Methods Med Res"},{"key":"1226_CR16","unstructured":"OPDIVO\u00ae (nivolumab) Prescribing information. Initial US approval: 2014. Revised: 4\/2019. https:\/\/packageinserts.bms.com\/pi\/pi_opdivo.pdf. Accessed 17 Jun 2019"},{"key":"1226_CR17","unstructured":"KEYTRUDA\u00ae (pembrolizumab) Prescribing information. Initial US approval: 2014. Revised: 4\/2019. https:\/\/www.merck.com\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf. Accessed 17 Jun 2019"},{"key":"1226_CR18","unstructured":"Yervoy\u00ae (ipilimumab) Prescribing information. Initial US approval: 2011. Revised: 7\/2018. https:\/\/packageinserts.bms.com\/pi\/pi_yervoy.pdf. Accessed 17 Jun 2019"},{"key":"1226_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1210\/er.2018-00006","volume":"40","author":"LS Chang","year":"2019","unstructured":"Chang LS, Barroso-Sousa R, Tolaney SM, Hodi FS, Kaiser UB, Min L (2019) Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr Rev 40:17\u201365. https:\/\/doi.org\/10.1210\/er.2018-00006","journal-title":"Endocr Rev"},{"key":"1226_CR20","first-page":"1005","volume":"28","author":"M Rastrelli","year":"2014","unstructured":"Rastrelli M, Tropea S, Rossi CR, Alaibac M (2014) Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. Vivo 28:1005\u20131011","journal-title":"Vivo"},{"key":"1226_CR21","first-page":"1","volume":"63","author":"SJ Henley","year":"2014","unstructured":"Henley SJ, Richards TB, Underwood JM, Eheman CR, Plescia M, McAfee TA (2014) Lung cancer incidence trends among men and women\u2014United States, 2005\u20132009. MMWR Morb Mortal Wkly Rep 63:1\u20135","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1226_CR22","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1210\/jc.2014-2306","volume":"99","author":"AT Faje","year":"2014","unstructured":"Faje AT, Sullivan R, Lawrence D, Tritos NA, Fadden R, Klibanski A, Nachtigall L (2014) Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab 99:4078\u20134085. https:\/\/doi.org\/10.1210\/jc.2014-2306","journal-title":"J Clin Endocrinol Metab"},{"key":"1226_CR23","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1158\/1078-0432.CCR-14-2353","volume":"21","author":"L Min","year":"2015","unstructured":"Min L, Hodi FS, Giobbie-Hurder A, Ott PA, Luke JJ, Donahue H, Davis M, Carroll RS, Kaiser UB (2015) Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clin Cancer Res 21:749\u2013755. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2353","journal-title":"Clin Cancer Res"},{"key":"1226_CR24","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1016\/j.ajpath.2016.08.020","volume":"186","author":"P Caturegli","year":"2016","unstructured":"Caturegli P, Di Dalmazi G, Lombardi M, Grosso F, Larman HB, Larman T, Taverna G, Cosottini M, Lupi I (2016) Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series. Am J Pathol 186:3225\u20133235. https:\/\/doi.org\/10.1016\/j.ajpath.2016.08.020","journal-title":"Am J Pathol"},{"key":"1226_CR25","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1530\/EJE-17-0810","volume":"178","author":"ES Scott","year":"2018","unstructured":"Scott ES, Long GV, Guminski A, Clifton-Bligh RJ, Menzies AM, Tsang VH (2018) The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma. Eur J Endocrinol 178:173\u2013180. https:\/\/doi.org\/10.1530\/EJE-17-0810","journal-title":"Eur J Endocrinol"},{"key":"1226_CR26","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ejca.2018.03.006","volume":"96","author":"A Mekki","year":"2018","unstructured":"Mekki A, Dercle L, Lichtenstein P, Marabelle A, Michot JM, Lambotte O, Le Pavec J, De Martin E, Balleyguier C, Champiat S, Ammari S (2018) Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1. Eur J Cancer 96:91\u2013104. https:\/\/doi.org\/10.1016\/j.ejca.2018.03.006","journal-title":"Eur J Cancer"},{"key":"1226_CR27","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.1158\/1078-0432.CCR-12-3243","volume":"19","author":"Y Feng","year":"2013","unstructured":"Feng Y, Roy A, Masson E, Chen TT, Humphrey R, Weber JS (2013) Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma. Clin Cancer Res 19:3977\u20133986. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-3243","journal-title":"Clin Cancer Res"},{"key":"1226_CR28","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","volume":"375","author":"AM Eggermont","year":"2016","unstructured":"Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM et al (2016) Prolonged survival in stage iii melanoma with ipilimumab adjuvant therapy. N Engl J Med 375:1845\u20131855. https:\/\/doi.org\/10.1056\/NEJMoa1611299","journal-title":"N Engl J Med"},{"key":"1226_CR29","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, Gobert A, Spano JP, Balko JM, Bonaca MP et al (2018) Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol 19:1579\u20131589. https:\/\/doi.org\/10.1016\/S1470-2045(18)30608-9","journal-title":"Lancet Oncol"},{"key":"1226_CR30","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4:1721\u20131728. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3923","journal-title":"JAMA Oncol"},{"key":"1226_CR31","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1126\/scitranslmed.3008002","volume":"6","author":"S Iwama","year":"2014","unstructured":"Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P (2014) Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med 6:230. https:\/\/doi.org\/10.1126\/scitranslmed.3008002","journal-title":"Sci Transl Med"},{"key":"1226_CR32","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/cncr.31200","volume":"124","author":"R Barroso-Sousa","year":"2018","unstructured":"Barroso-Sousa R, Ott PA, Hodi FS, Kaiser UB, Tolaney SM, Min L (2018) Endocrine dysfunction induced by immune checkpoint inhibitors: practical recommendations for diagnosis and clinical management. Cancer 124:1111\u20131121. https:\/\/doi.org\/10.1002\/cncr.31200","journal-title":"Cancer"},{"key":"1226_CR33","doi-asserted-by":"publisher","first-page":"857","DOI":"10.2165\/00002018-200427120-00003","volume":"27","author":"M Lindquist","year":"2004","unstructured":"Lindquist M (2004) Data quality management in pharmacovigilance. Drug Saf 27:857\u2013870. https:\/\/doi.org\/10.2165\/00002018-200427120-00003","journal-title":"Drug Saf"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-020-01226-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40618-020-01226-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-020-01226-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T23:23:50Z","timestamp":1617233030000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40618-020-01226-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,1]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["1226"],"URL":"https:\/\/doi.org\/10.1007\/s40618-020-01226-4","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,1]]},"assertion":[{"value":"23 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"No competing financial interests exist.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}